3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Mantle-Cell
5
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, B-Cell
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Burkitt Lymphoma
1
Advanced Haematological Malignancies
1
Interventions
pembrolizumab
25
Gemcitabine
21
Nivolumab
17
Cisplatin
17
atezolizumab
14
Carboplatin
11
avelumab
9
vinflunine
7
Ipilimumab
7
Paclitaxel
6
Docetaxel
5
enfortumab vedotin
4
cabazitaxel
4
Pemetrexed
4
Mitomycin
4
cabozantinib
3
Taxes
3
Rogaratinib
3
Magnetic Resonance Spectroscopy
3
Injections
3
Albumin-Bound Paclitaxel
3
tremelimumab
2
sacituzumab govitecan
2
pemigatinib
2
niraparib
2
lenvatinib
2
bempegaldesleukin
2
apatorsen
2
XRP6258
2
Vitamin D
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Transitional Cell
×
acalabrutinib
×
Clear all
NCT02351739
2019-09-10
KEYNOTE143
Acerta Pharma BV
Phase 2
Completed
78 enrolled
10 charts